Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€18.16

€18.16

-2.490%
-0.465
-2.490%
€26.64
 
23.08.24 / Tradegate WKN: A0LCUL / Symbol: CPRX / Name: Catalyst Pharma / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Catalyst Pharmaceutical Partners Inc Stock

A loss of -2.490% shows a downward development for Catalyst Pharmaceutical Partners Inc.
Catalyst Pharmaceutical Partners Inc is currently one of the favorites of our community with 14 Buy predictions and no Sell predictions.
As a result the target price of 26 € shows a positive potential of 43.21% compared to the current price of 18.16 € for Catalyst Pharmaceutical Partners Inc.
For the coming years our community has positive and negative things to say abot the Catalyst Pharmaceutical Partners Inc stock. Criterium "Revenue growth" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.

Pros and Cons of Catalyst Pharmaceutical Partners Inc in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Catalyst Pharmaceutical Partners Inc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Catalyst Pharmaceutical Partners Inc -2.490% 0.693% 12.206% 39.493% 16.828% 274.484% 238.145%
Evolus Inc 2.940% 16.667% 21.739% 64.706% 54.696% 51.351% -
Ardelyx Inc. 5.770% 6.941% 7.836% 67.751% -1.903% 364.754% 79.034%
Coherus Bioscien. 4.560% 8.696% -18.879% -71.053% -59.293% -90.553% -93.737%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-16

Catalyst Pharma (CPRX) appears to be fundamentally improving its financial position, owing to the growth seen in recent financial statements. Observing the company's financials, the trend of increasing revenues, net income, total assets, and shareholder's equity is noticeable. This indicates that Catalyst Pharma has been experiencing a growth phase in its business operations in the market.

*Pros: *

Revenue Growth: The company is experiencing substantial growth in total revenue from 2020 to 2022, which is positive for its financial position. This revenue growth is attributed to the company's ability to successfully market and sell its products, positively reflecting its business operations.

Comments

Prediction Buy
Perf. (%) 6.89%
Target price 27.465
Change
Ends at 12.08.25

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its price target raised by analysts at HC Wainwright from $26.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for CPRX provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 8.84%
Target price 27.477
Change
Ends at 09.08.25

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its price target raised by analysts at Truist Financial Co. from $25.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for CPRX provided by MarketBeat
Show more

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for CPRX provided by MarketBeat
Show more